Q4 FY26Published 27 May 2026Call held 27 May 2026
SAIPARENT Q4 FY26 Earnings Call Transcript & Analysis
Consolidated FY26 Revenue₹381 cr+133% YoYConsolidated FY26 EBITDA₹47 cr+18% YoYConsolidated Q4 FY26 Revenue₹198 crConsolidated Q4 FY26 EBITDA₹29 crConsolidated Q4 FY26 EBITDA Margin15%
Consolidated FY26 Revenue ₹381 cr (+133% YoY); Consolidated FY26 EBITDA ₹47 cr (+18% YoY); Consolidated Q4 FY26 Revenue ₹198 cr. FY26 was a transformational year, including a successful public listing and the acquisition of Noumed Pharmaceuticals.
Read full transcript & analysis